Larkspur Biosciences

About Larkspur Biosciences

Targeting enzymes that control cancer cell state and fitness make cancer cells susceptible to intrinsic and immune-mediated killing but drugging these pathways has been limited by poor tractability. Larkspur develops small molecules that overcome these limitations, decreasing cancer cell fitness and sensitizing them to intrinsic and immune-driven mechanisms of killing. LarkX, our proprietary machine-learning-enabled gene signature platform, identifies pathways with cancer cell-intrinsic adaptations that drive immune evasion. This identifies novel targets that mediate pathological cell-to-cell communication. Larkspur’s clinical development focuses on biomarker-driven cancer patient cohorts to achieve early proof-of-concept. Our first-in-class pipeline programs are initially focused on colorectal cancer (CRC), with opportunities to expand to multiple cancers. We believe that transformational discoveries are found at the interface between disciplines. With a proven track record of drug discovery and development, our team is passionate about solving hard problems and driven to deliver new medicines to cancer patients with significant unmet needs. At Larkspur, we grow together, building a culture that highly values joy, trust, and courage.

View contact profiles from Larkspur Biosciences